---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-034678"
form_type: "8-K"
ticker: "SPRY"
cik: "0001671858"
company_name: "ARS Pharmaceuticals, Inc."
filed_at: "2024-03-21T23:59:59+00:00"
generated_at: "2026-06-04T09:55:47.143092+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ARS Pharma to submit CRL response in early Q2 2024; Q4 net loss $7.2M, cash $228.4M

## Summary
- CRL response for neffy (epinephrine nasal spray) to be submitted early Q2 2024; FDA action and potential launch expected H2 2024.
- Phase 2 urticaria trial met primary endpoints with rapid symptom control; outpatient study planned later in 2024.
- Cash, equivalents and short-term investments $228.4M as of Dec 31, 2023; runway at least three years.
- Net loss $7.2M in Q4, $54.4M full year 2023; R&D costs $3.4M in Q4, G&A $6.8M.
- EMA MAA decision for neffy expected mid-2024; new U.S. patent issued covering intranasal epinephrine methods.

## SEC filing metadata
- accession: 0000950170-24-034678
- form_type: 8-K
- ticker: SPRY
- cik: 0001671858
- company_name: ARS Pharmaceuticals, Inc.
- filed_at: 2024-03-21T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671858/000095017024034678/0000950170-24-034678-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671858/000095017024034678/spry-20240321.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-034678
- JSON: https://secwatch.observer/filing/0000950170-24-034678.json
- Plain text: https://secwatch.observer/filing/0000950170-24-034678.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.